Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): A 6 year experience of the Cologne AML cohort

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1466-1471

  Vehreschild, J J ^a   Ruping M J G T ^a   Wisplinghoff, H ^a   Farowski, F ^a   Steinbach, A ^a   Sims, R ^a   Stollorz, A ^a   Kreuzer, K A ^a   Hallek, M ^a   Bangard, C ^a   Cornely, O A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Antifungals; Aspergillosis; Cytarabine; Neutropenia; Triazoles

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; POLYENE; POSACONAZOLE; TIOGUANINE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYCOSIS; OVERALL SURVIVAL; TREATMENT RESPONSE; ADOLESCENT; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; COMPLICATION; GERMANY; INCIDENCE; LENGTH OF STAY; MIDDLE AGED; MYCOSES; PROCEDURES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHEMOPREVENTION; FEMALE; GERMANY; HUMANS; INCIDENCE; LENGTH OF STAY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; POLYENES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 77954187715     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq121     Document Type: Article

References (31)

1. Lass-Florl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52: 197-205.
2. Cuenca-Estrella M, Bernal-Martinez L, Buitrago MJ et al. Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents 2008; 32 Suppl 2: S143-7.
3. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
4. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
5. Pagano L, Caira M, Picardix M et al. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality-SEIFEM-C report. Clin Infect Dis 2007; 44: 1524-5.
6. Cesaro S, Giacchino M, Locatelli F et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007; 7: 28.
7. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
8. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
9. Marr KA. Antifungal therapy for febrile neutropenia: issues in clinical trial design. Curr Opin Investig Drugs 2004; 5: 202-7.
10. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
11. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
12. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
13. Glockner A, Steinbach A, Vehreschild JJ et al. Treatment of invasive candidiasis with echinocandins. Mycoses 2009; 52: 476-86.
14. European LeukemiaNet, European Group for Blood & Marrow Transplantation, European Organization for Research and Treatment of Cancer and International Immunocompromised Host Society. 2007 Update of the ECIL-1 Guidelines for Antifungal Prophylaxis in Leukemia Patients, Including Illogeneic HSCT Recipients. http://www.ichs.org/Ecilslides/ECIL2%20%20Antifungal%20prophylaxis%20update%202007. pdf (9 March 2010, date last accessed).
15. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis-has the principle been proven? N Engl J Med 2007; 356: 409-11.
16. Farowski F, Vehreschild JJ, Cornely OA. Posaconazole: a next-generation triazole antifungal. Future Microbiol 2007; 2:231-43.
17. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
18. Cornely OA, Bohme A, Reichert D et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008; 61: 939-46.
19. Rotstein C, Bow EJ, Laverdiere M et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331-40.
20. Rembold CM. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. JFam Pract 1996; 42: 577-86.
21. Green H, Paul M, Vidal L et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007; issue 3: CD005590.
22. Cornely OA, Ullmann AJ. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 2008; 46: 1626-7; author reply 1627-8.
23. Vehreschild JJ, Ruping MJ, Steinbach A et al. Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. Expert Opin Pharmacother 2010; 11: 95-113.
24. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803; quiz 804-5.
25. Lech-Maranda E, Seweryn M, Giebel S et al. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). Int J Infect Dis 2010; 14: e132-40.
26. Gangat N, Khan MA, Mujib M et al. Pulmonary infiltrates during chemotherapy-induced febrile neutropenia: incidence, patterns and outcomes. J Pak Med Assoc 2004; 54: 285-8.
27. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med 1983; 99: 544-50.
28. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
29. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies.Clin Infect Dis 2006; 42: 1584-91.
30. Cordonnier C, Maury S, Pautas C et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-8.
31. Vehreschild JJ, Sieniawski M, Reuter S et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents 2009; 34: 446-50.